Katherine Goodrich Sells 2,954 Shares of Tarsus Pharmaceuticals (NASDAQ:TARS) Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Director Katherine Goodrich sold 2,954 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $62.08, for a total value of $183,384.32. Following the transaction, the director owned 2,233 shares in the company, valued at $138,624.64. This trade represents a 56.95% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tarsus Pharmaceuticals Price Performance

Tarsus Pharmaceuticals stock opened at $63.16 on Friday. The stock has a market capitalization of $2.72 billion, a P/E ratio of -55.40 and a beta of 0.49. The company’s fifty day moving average price is $63.35 and its 200 day moving average price is $69.43. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.71 and a current ratio of 3.74. Tarsus Pharmaceuticals, Inc. has a 1 year low of $38.51 and a 1 year high of $85.25.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.24. Tarsus Pharmaceuticals had a negative net margin of 9.02% and a negative return on equity of 14.19%. The company had revenue of $162.05 million during the quarter, compared to analysts’ expectations of $149.60 million. As a group, equities research analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -0.59 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. Rockefeller Capital Management L.P. lifted its position in Tarsus Pharmaceuticals by 15.5% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company’s stock worth $105,000 after buying an additional 172 shares in the last quarter. Parallel Advisors LLC increased its stake in shares of Tarsus Pharmaceuticals by 139.2% in the 1st quarter. Parallel Advisors LLC now owns 500 shares of the company’s stock worth $35,000 after acquiring an additional 291 shares during the last quarter. State of Wisconsin Investment Board raised its holdings in shares of Tarsus Pharmaceuticals by 1.1% during the 4th quarter. State of Wisconsin Investment Board now owns 31,912 shares of the company’s stock worth $2,613,000 after acquiring an additional 332 shares during the period. Federated Hermes Inc. boosted its position in shares of Tarsus Pharmaceuticals by 0.6% during the 2nd quarter. Federated Hermes Inc. now owns 55,021 shares of the company’s stock valued at $2,229,000 after acquiring an additional 339 shares during the last quarter. Finally, Valeo Financial Advisors LLC boosted its position in shares of Tarsus Pharmaceuticals by 11.1% during the 4th quarter. Valeo Financial Advisors LLC now owns 3,915 shares of the company’s stock valued at $321,000 after acquiring an additional 392 shares during the last quarter. 90.01% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have commented on TARS. Zacks Research lowered Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 25th. HC Wainwright reiterated a “buy” rating and set a $88.00 price target on shares of Tarsus Pharmaceuticals in a research report on Monday, May 4th. Guggenheim increased their price objective on Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Tuesday, April 21st. Finally, Oppenheimer started coverage on shares of Tarsus Pharmaceuticals in a report on Friday, April 24th. They set an “outperform” rating and a $98.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Tarsus Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $90.67.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.